Related Experiment Video
Updated: Nov 20, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.8K
Chimeric antigen receptor T-cell therapy for melanoma
Azadehsadat Razavi1,2,3, Mahsa Keshavarz-Fathi2,4, John Pawelek5
1Department of Animal Biology, Faculty of Biology Sciences, University of Kharazmi, Tehran, Iran.
Expert Review of Clinical Immunology
|January 22, 2021
Summary
Chimeric antigen receptor (CAR) T cell therapy shows promise for treating melanoma by reprogramming T cells to target tumor antigens. Ongoing clinical trials are evaluating its effectiveness for this challenging cancer.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T cell therapy, initially successful in hematologic cancers, is now being explored for solid tumors like melanoma.
- Developing CAR T cells for melanoma requires targeting specific tumor antigens (e.g., CSPG4, CD70, GD2) and optimizing co-stimulatory signaling domains.
Purpose of the Study:
- To review various CAR T cell therapy approaches for melanoma.
- To discuss the current status, challenges, and future directions of CAR T cell therapy in melanoma treatment.
Main Methods:
- A literature search was conducted across PubMed, Google Scholar, and Clinicaltrials.gov.
- Relevant published papers and clinical trials were screened based on predefined eligibility criteria.
Main Results:
- CAR T cell therapy presents a potential treatment option for melanoma, particularly for treatment-resistant cases.
- Clinical trials are actively investigating the efficacy and safety of CAR T cell therapy for melanoma.
Conclusions:
- CAR T cell therapy holds promise for melanoma treatment despite existing challenges and potential adverse events.
- Further clinical evaluation is essential to establish the role of CAR T cell therapy in melanoma management.
